Solasia Pharma KK
TSE:4597
Solasia Pharma KK
TSE:4597
Price:
27 JPY
Market Closed
Updated:
May 14, 2024
Solasia Pharma KK
Income from Continuing Operations
|
Solasia Pharma KK
Income from Continuing Operations Peer Comparison
Comparables:
2160
4587
4974
J
7774
S
4599
Competitive Income from Continuing Operations Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Income from Continuing Operations | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Solasia Pharma KK
TSE:4597
|
Income from Continuing Operations
-¥1.1B
|
CAGR 3-Years
35%
|
CAGR 5-Years
14%
|
CAGR 10-Years
N/A
|
|
|
GNI Group Ltd
TSE:2160
|
Income from Continuing Operations
¥9.5B
|
CAGR 3-Years
91%
|
CAGR 5-Years
118%
|
CAGR 10-Years
N/A
|
|
|
PeptiDream Inc
TSE:4587
|
Income from Continuing Operations
¥3B
|
CAGR 3-Years
-12%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
N/A
|
|
|
Takara Bio Inc
TSE:4974
|
Income from Continuing Operations
¥1.6B
|
CAGR 3-Years
-39%
|
CAGR 5-Years
-14%
|
CAGR 10-Years
2%
|
|
J
|
Japan Tissue Engineering Co Ltd
TSE:7774
|
Income from Continuing Operations
-¥157.3m
|
CAGR 3-Years
22%
|
CAGR 5-Years
15%
|
CAGR 10-Years
17%
|
|
S
|
StemRIM Inc
TSE:4599
|
Income from Continuing Operations
¥168.4m
|
CAGR 3-Years
-21%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
See Also
What is Solasia Pharma KK's Income from Continuing Operations?
Income from Continuing Operations
-1.1B
JPY
-1.1B
JPY
Based on the financial report for Dec 31, 2023, Solasia Pharma KK's Income from Continuing Operations amounts to -1.1B JPY.
What is Solasia Pharma KK's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 5Y
14%
14%
Over the last year, the Income from Continuing Operations growth was 56%. The average annual Income from Continuing Operations growth rates for Solasia Pharma KK have been 35% over the past three years , 14% over the past five years .
You don't have any saved screeners yet
